The Center for Quantitative Cancer Imaging (CQCI) was founded with the goal of providing researchers, clinicians, and the people of Utah with state of the art molecular imaging technologies to enable high quality research and assist investigators in therapeutic development, diagnosing disease and monitoring therapy.
One goal of the Preclinical Research Imaging arm of the CQCI is to assist researchers in the preclinical development of novel treatments using non-invasive imaging techniques. Ideally this goal assists researchers in more rapid and accurate assessment of new treatments and novel therapeutic/diagnostic compounds.
Randy Jensen, MD
Evaluation of imaging biomarkers of pseudo-progression in a rat brain tumor model
Kathryn Morton, MD
Evaluation of rat models of inflammation
Sunil Sharma, MD
Evaluation of a novel LSD-1 inhibitor in Ewing sarcoma rodent models
Jeffrey T. Yap, PhD
Development of quantitative imaging biomarkers for assessing response to sarcoma therapy
SARC Sarcoma SPORE: “Project 4: Development of quantitative imaging biomarkers for assessing response to sarcoma therapy.” HCI PI: Jeffrey Yap, SPORE PI: Raphael Pollock, The Ohio State University.
|This project seeks to develop new imaging approaches using MRI and PET to non-invasively measure various aspects of tumor biology and pathophysiology in response to conventional and experimental chemotherapies. This will enable a powerful set of tools to evaluate treatment efficacy and ultimately improve the development of new drugs and clinical management of sarcoma patients. This is a subcontract to SARC.|